Family Intervention Program for Preventing Drug Abuse Among Disadvantaged Children in Urban Slums

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03472222
Recruitment Status : Not yet recruiting
First Posted : March 21, 2018
Last Update Posted : March 21, 2018
OBC Morch, BJP, India
Information provided by (Responsible Party):
NMP Medical Research Institute

Brief Summary:
Substance abuse remain critical problems in both developed and developing countries. Under privileged communities where health and economic system is weakest, use of drugs and illicit substances starts during adolescence and young adulthood. This not just affect physical development, mental health and social integration, but also family formation and stability, deviant behaviour, sexual behaviour and involvement, educational pursuits, livelihood pursuits. Therefore, emphasises the need for preventive education at this impressionable age.

Condition or disease Intervention/treatment Phase
Drug Abuse Behavioral: family intervention program Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Quasi experimental design
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Family Intervention Program for Preventing Drug Abuse Among Disadvantaged Children in Urban Slums
Estimated Study Start Date : June 28, 2018
Estimated Primary Completion Date : December 30, 2018
Estimated Study Completion Date : April 25, 2019

Arm Intervention/treatment
Experimental: Family Intervention Program Behavioral: family intervention program
family intervention program will include work with de-addiction program, counselling and supportive therapies with the support of family.

Primary Outcome Measures :
  1. Frequency, intensity, and duration of craving [ Time Frame: 6 weeks ]
    Change from baseline in the measure of the Penn Alcohol and Craving Scale

Secondary Outcome Measures :
  1. Consequences of Drug Use [ Time Frame: 6 weeks ]
    Change from baseline in Alcohol and Drug Use Consequences Scale

  2. Well being [ Time Frame: 6 weeks ]
    The Well-Being Index (WBI), 5-item scale used to assess changes in general well-being.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   7 Years to 13 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Parental consent to participate

Exclusion Criteria:

  • Family not involved in de-addiction program
  • Planning to move the area
  • Mental incapacity to consent or participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03472222

Contact: Madan l CHOUHAN +919315625257

OBC Morcha Not yet recruiting
Yamunanagar, Haryana, India
Contact: Madan Chouhan    +919315625257   
Sponsors and Collaborators
NMP Medical Research Institute
OBC Morch, BJP, India
Principal Investigator: Madan Chouhan OBC Morch, BJP

Responsible Party: NMP Medical Research Institute Identifier: NCT03472222     History of Changes
Other Study ID Numbers: NMP/10122
First Posted: March 21, 2018    Key Record Dates
Last Update Posted: March 21, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders